Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid in Pediatric Osteogenesis Imperfecta
NCT00063479Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2003
- Primary completion
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of zoledronic acid in osteogenesis imperfecta (OI) (2 arms), sponsored by Novartis. Primary endpoint: Change in lumbar spine bone mineral density at 12 months. Started Jun 2003; status: completed.
02
Drugs
zoledronic acid
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on NCT00063479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00063479.